Oruka Therapeutics, Inc. — Director's Dealing 2012

Feb 15, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARCA biopharma, Inc. (ABIO)
CIK: 0000907654
Period of Report: 2012-02-10

Reporting Person: SOBEL BURTON E (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-02-10	Option to Purchase Common Stock	$1.00	A	3500	Acquired	2022-02-10	Common Stock (3500)	Direct
2012-02-10	Option to Purchase Common Stock	$1.00	A	3500	Acquired	2022-02-10	Common Stock (3500)	Direct

Footnotes

F1: The options vest in 12 equal monthly installments measured from 1/1/12. If the Reporting Person's service as a director of the Issuer terminates in connection with or at anytime following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.